Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Inhibitors of DNA Methylation

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Institut des Biomolécules Max Mousseron Pôle Chimie Balard (IBMM); Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM); Université de Montpellier (UM); Chimie biologique épigénétique - Epigenetic Chemical Biology (EpiCBio); Institut Pasteur Paris (IP)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité); Ecole Doctorale Frontiere de l’Innovation en Recherche et Education (ED 474 FIRE); Université Paris Cité (UPCité)-Université Paris Sciences et Lettres (PSL); ANR-17-EURE-0012,EURIP,Ecole Universitaire de Recherche Interdisciplinaire de Paris(2017)
    • بيانات النشر:
      HAL CCSD
    • الموضوع:
      2022
    • Collection:
      Université de Montpellier: HAL
    • نبذة مختصرة :
      International audience ; DNA methylation is involved in numerous biological processes and is deregulated in human diseases. The modulation of the activity of the enzymes and proteins in charge of DNA methylation, for example, DNA methyltransferases (DNMTs), can represent a powerful strategy to alter DNA methylation patterns and restore biological processes that are aberrant in diseases. In this chapter, we present examples of inhibitors of DNMTs (DNMTi). We review their fields of application either as therapeutic molecules, for example, in cancers, cardiovascular, neurological, and infectious diseases or as bioengineering tools. Finally, novel strategies to target DNA methylation and overcome the limits of single DNMT inhibitors will be described. These strategies consist in either targeting the methyl group reader proteins rather than targeting directly DNMTs or to combine within the same molecule a DNMT inhibitor with an additional active moiety, e.g., HDAC inhibitor, to improve efficacy and lower secondary effect of such drug.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/36350520; PUBMED: 36350520
    • الرقم المعرف:
      10.1007/978-3-031-11454-0_17
    • الدخول الالكتروني :
      https://hal.science/hal-04269122
      https://hal.science/hal-04269122v1/document
      https://hal.science/hal-04269122v1/file/Arimondo-Chap17_Ed2_V-HAL.pdf
      https://doi.org/10.1007/978-3-031-11454-0_17
    • Rights:
      http://hal.archives-ouvertes.fr/licences/copyright/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.2AD15B61